Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Epigenetic drug discovery has seen significant progress, with numerous small molecule inhibitors entering clinical trials for diverse malignancies.
• While clinical studies explore epigenetic therapies in monotherapy and combination regimens, preclinical research has primarily focused on single-agent efficacy.

Purpose of the Study:

• To review FDA-approved epigenetic drugs and those in clinical investigation for various cancer types.
• To discuss emerging strategies, including PROTACs and CRISPR/Cas9, for enhancing the antitumor effects of epigenetic inhibitors.
• To explore rational scaffold design for isoform-selective enzyme targeting and multi-targeting agents as alternatives to combination therapy.

Main Methods:

• Literature review of FDA-approved epigenetic drugs and ongoing clinical investigations.
• Analysis of emerging therapeutic modalities such as Proteolysis Targeting Chimeras (PROTACs) and CRISPR/Cas9 gene editing.
• Discussion of scaffold fabrication strategies for enzyme isoform selectivity and multi-targeting agents.

Main Results:

• An update on the current landscape of epigenetic inhibitors in clinical development for cancer treatment.
• Identification of pragmatic strategies leveraging novel approaches to improve epigenetic therapy efficacy.
• Exploration of rational design principles for developing advanced epigenetic therapeutics.

Conclusions:

• Epigenetic therapy holds significant promise, with ongoing advancements in drug discovery and therapeutic strategies.
• Emerging technologies like PROTACs and CRISPR/Cas9, alongside rational drug design, are poised to enhance antitumor effects.
• The development of multi-targeting agents offers a promising alternative to traditional combination therapies in cancer treatment.